Literature DB >> 6340821

Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.

S Meijer, D T Sleijfer, N H Mulder, W J Sluiter, J Marrink, H S Koops, T M Brouwers, J Oldhoff, G K van der Hem, E Mandema.   

Abstract

Renal function in 24 patients with disseminated nonseminomatous testicular carcinoma treated with combination chemotherapy including cis-platinum was examined prospectively. Renal function was monitored by several determinations of glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and serum creatinine, and beta-2-microglobulin. A reduction in GFR and ERPF was found at the end of the induction chemotherapy and at six weeks thereafter. Median GFR and ERPF decreased both 23% (P less than 0.01). Serum creatinine and beta-2-microglobulin concentrations however did not rise. It is suggested that under the influence of chemotherapy with platinum the production of creatinine and beta-2-microglobulin is decreased rendering their serum levels unsuitable as parameters of renal function.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6340821     DOI: 10.1002/1097-0142(19830601)51:11<2035::aid-cncr2820511113>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a Cancer and Leukemia Group B study.

Authors:  J B Hargis; J R Anderson; K J Propert; M R Green; D A Van Echo; R B Weiss
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Acute and long-term nephrotoxicity of cis-platinum in man.

Authors:  S Groth; H Nielsen; J B Sørensen; A B Christensen; A G Pedersen; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Measurement of glomerular function during cisplatin therapy.

Authors:  D G Waller; L Juer; J S Fleming
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 5.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 6.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

7.  Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function.

Authors:  J J Offerman; S Meijer; D T Sleijfer; N H Mulder; A J Donker; H S Koops; G K van der Hem
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Measures of renal function in patients with cisplatin-related chronic renal disease.

Authors:  E Reed; J Jacob; O Brawley
Journal:  J Natl Med Assoc       Date:  1991-06       Impact factor: 1.798

10.  Beta-2-microglobulin excretion: an indicator of long term nephrotoxicity during cis-platinum treatment?

Authors:  P G Sørensen; M H Nissen; S Groth; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.